Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective studyFrontiers in Oncology, 2024, v.14, 1363385
Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)Cancer Research and Treatment, 2024, v.56 no.3, 956-966
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneAmerican Journal of Gastroenterology, 2023, v.118 no.8, 1373-1380
Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II studyFRONTIERS IN ONCOLOGY, 2023, v.13, 998014
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) StudyCANCER RESEARCH AND TREATMENT, 2023, v.55 no.4, 1355-1362
Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From KoreaJOURNAL OF KOREAN MEDICAL SCIENCE, 2023, v.38 no.41, e328
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)FRONTIERS IN ONCOLOGY, 2023, v.13, 1209110
Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemiaCancer Medicine, 2023, v.12 no.7, 8073-8082
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantationBlood Cancer Journal, 2023, v.13 no.1, 95
A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatmentFRONTIERS IN ONCOLOGY, 2022, v.12, 989984
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemiaThe Korean Journal of Internal Medicine, 2022, v.37 no.4, 841-850
Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909)Bone Marrow Transplantation, 2022, v.57 no.12, 1797-1802
Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of HematologyClinical Lymphoma, Myeloma and Leukemia, 2022, v.22 no.10, e931-e937
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneInternational Journal of Hematology, 2021, v.113 no.1, 81-91
Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in AsiaThe Lancet Regional Health - Western Pacific, 2021, v.10, 100126
Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in AsiaInternational Journal of Hematology, 2021, v.114 no.3, 355-362
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CTBLOOD CANCER JOURNAL, 2021, v.11 no.12, 190
Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myelomaSupportive Care in Cancer, 2021, v.29 no.9, 4969-4977
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysisANNALS OF HEMATOLOGY, 2020, v.99 no.6, 1283-1291
Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCRLaboratory Medicine Online, 2020, v.10 no.4, 321-325
Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysisLEUKEMIA & LYMPHOMA, 2020, v.61 no.11, 2714-2721
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)BRITISH JOURNAL OF HAEMATOLOGY, 2020, v.189 no.2, 303-312
Peroxiredoxin 3 has important roles on arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line via hyperoxidation of mitochondrial specific reactive oxygen speciesMolecules and Cells, 2020, v.43 no.9, 813-820
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)American Journal of Hematology, 2020, v.95 no.4, 0
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic LeukemiaYONSEI MEDICAL JOURNAL, 2020, v.61 no.6, 452-459
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)Annals of Hematology, 2020, v.99 no.2, 309-319
A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 StudyBiology of Blood and Marrow Transplantation, 2019, v.25 no.7, 1312-1319
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring SystemCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, v.19 no.10, 656-664
Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysisANNALS OF HEMATOLOGY, 2019, v.98 no.10, 2273-2281
Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional DyspepsiaJOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2019, v.25 no.2, 212-221
Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapyThrombosis Research, 2019, v.183, 131-135
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trialKOREAN JOURNAL OF INTERNAL MEDICINE, 2019, v.34 no.5, 1125-1135
Clinicopathological characteristics of hyperdiploidy with high-risk cytogenetics in multiple myelomaAnnals of Laboratory Medicine, 2018, v.38 no.2, 160-164
Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, v.33 no.19
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patientsANNALS OF HEMATOLOGY, 2018, v.97 no.6, 955-965
Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01CANCER RESEARCH AND TREATMENT, 2018, v.50 no.2, 590-598
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, v.24 no.5, 923-929
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphomaANNALS OF ONCOLOGY, 2018, v.29 no.1, 256-263
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple MyelomaACTA HAEMATOLOGICA, 2018, v.140 no.3, 146-156
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myelomaONCOTARGET, 2017, v.8 no.23, 37605-37618
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapyAmerican Journal of Hematology, 2017, v.92 no.12, 1280-1286
Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphomaONCOTARGET, 2017, v.8 no.54, 92171-92182
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCLINICAL CANCER RESEARCH, 2017, v.23 no.23, 7180-7188
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)ONCOTARGET, 2017, v.8 no.45, 79517-79526
CLINICOPATHOLOGIC CHARACTERISTICS ASSOCIATED WITH NATURAL KILLER CELL ACTIVITY BY MEASUREMENT OF INTERFERON-GAMMA IN HEMATOLOGIC MALIGNANCIESHAEMATOLOGICA, 2016, v.101, 661-661
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patientsLeukemia and Lymphoma, 2016, v.57 no.2, 341-347
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort studyONCOTARGET, 2016, v.7 no.44, 72033-72043
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID studyHAEMATOLOGICA, 2016, v.101 no.6, 717-723
MITOCHONDRIAL SPECIFIC ROS HYPEROXIDATION VIA PEROXIREDOXIN III HAS IMPORTANT ROLES ON ARSENIC TRIOXIDE INDUCED APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIAHAEMATOLOGICA, 2016, v.101, 672-672
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of KoreaANNALS OF HEMATOLOGY, 2016, v.95 no.6, 911-919
Two Cases of Medical Device-Related Corynebacterium striatum Infection: A Meningitis and A SepsisAnnals of Clinical Microbiology, 2016, v.19 no.1, 28-31
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeOncotarget, 2015, v.6 no.42, 44985-44994
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic SyndromeACTA HAEMATOLOGICA, 2015, v.134 no.1, 40-48
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell LymphomaBiology of Blood and Marrow Transplantation, 2015, v.21 no.9, 1597-1604
Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical TrialBLOOD, 2015, v.126 no.23
Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter studyAnnals of Hematology, 2015, 24 NOV 2015, 1-8
Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progressionINTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, v.37 no.2, 181-189
PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDYHAEMATOLOGICA, 2015, v.100, 433-434
Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with RadotinibBLOOD, 2015, v.126 no.23
Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH RearrangementsANNALS OF LABORATORY MEDICINE, 2015, v.35 no.1, 128-131
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in KoreaKorean Journal of Internal Medicine, 2015, v.30 no.5, 675-683
Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysisCancer Research and Treatment, 2015, v.47 no.2, 173-181
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapyJournal of Clinical Virology, 2015, v.73, 64-69
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, v.94 no.6, 504-510
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter studyBioMed Research International, 2014
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry studyAnnals of Hematology, 2014, v.93 no.8, 1353-1361
Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in KoreaBIOMED RESEARCH INTERNATIONAL, 2014
Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart diseaseKOREAN JOURNAL OF INTERNAL MEDICINE, 2014, v.29, 445-453
Incidence of venous thromboembolism following major surgery in Korea: From the Health Insurance Review and Assessment Service databaseJournal of Thrombosis and Haemostasis, 2014, v.12 no.7
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patientsANNALS OF HEMATOLOGY, 2014, v.93 no.1, 113-121
Prevention of Venous Thromboembolism, 2nd Edition : Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice GuidelinesJOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.2, 164-171
Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies : A Multicenter, Prospective, Open-Label, Observational Study in KoreaJOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.1, 61-68
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis : a multicenter, prospective, open-label, observational study in KoreaANNALS OF HEMATOLOGY, 2014, v.93 no.1, 33-42
Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancerTUMORI, 2014, v.100 no.1, 80-86
Topoisomerase II alpha and microtubuleassociated protein-tau as a predictive marker in axillary lymph node positive breast cancerTumori, 2014, v.100 no.1, 80-86